Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Big data revolution driving $13.4 billion Healthtech M&A deals says HampletonPartners

  • Amazon, Apple, Google and IBM healthtech investments are forcing incumbents to make defensive M&A deals
  • Record private equity investment in healthtech

The latest Healthtech M&A Market Report from international technology mergers and acquisitions advisors, Hampleton Partners, reveals how Big Data is fast becoming the common currency that lies at the heart of high-value business models in the healthtech sector.

In addition to booming strategic investment in the sector, the first half of 2018 saw record private equity investment and five multi-billion-dollar deals, pushing the total disclosed transaction value to $13.4 billion with a 30-month trailing disclosed EV\EBITDA ratio in excess of 16x.

Download the full Hampleton Partners Healthtech M&A Market Report: https://hampletonpartners.com/healthtech-report-2018

Total Healthtech MA Transaction Volume 2018 Hampleton Partners
Total Healthtech MA Transaction Volume 2018 Hampleton Partners

The data revolution in healthtech

Billions of individual electronic health records (EHR) are replacing paper files and the data from decades of medical research and clinical trials need to be stored. Data management and analytics platforms and medical collaboration software are in demand to take advantage of the huge potential the data revolution offers to advance medicine.

Jonathan Simnett, director and healthtech sector principal, Hampleton Partners, said:

“The data revolution is helping transform healthcare and is offering individuals, as well as clinicians, the opportunity to track, manage and improve health states in real-time by using healthtech wearables and personalised apps.

“These trillions of health and well-being data points all need monitoring and analysing to provide the effective diagnostics that practitioners need to improve outcomes. Hampleton expects companies expert in big data analytics, and those using new technologies such as blockchain and artificial intelligence, which increase the effectiveness of healthcare services, are going to be in demand going forward.”

Tech giants’ healthtech ambitions

But the healthcare market is not just going through a technology inflection point. There are profound disruptive influences at play, as companies from outside of the traditional healthcare space bring new expertise and business models to the sector, competing with already highly acquisitive incumbents such as Philips, IMSHealth, Allscripts, Ability, Roper and Harris.

Amazon’s purchase of online pharmacy PillPack, for a reported value of just under $1.0 billion, underscores the company’s ambitions in healthcare after its joint venture announcement for employee healthcare services provision with Berkshire Hathaway and JPMorgan.  The potential for Amazon to combine its eCommerce, video platform, massive outsourced web services expertise and customer reach into a one-stop shop for consumer verticals like healthcare, could trigger further defensive acquisitions in the months and years to come.

Total Number of Healthtech MA Deals 2013 - 2018 Hampleton Parters
Total Number of Healthtech MA Deals 2013 – 2018 Hampleton Parters

Private equity invests billions in healthtech

The sector’s largest deal in the first half year was the $4.9 billion cash acquisition of Cotiviti Holdings, a healthcare analytics and payments business, by Verscend Technologies, a portfolio company of Veritas Capital. The acquisition, valued at 19.7x EBITDA and at a 136 percent premium to Cotiviti’s IPO common stock price, demonstrated the heightened willingness of private equity investors to chase big-ticket deals in healthcare.

The healthtech sector’s second largest transaction was the $2.1 billion offer from Platinum Equity for Johnson & Johnson’s struggling LifeScan unit, a manufacturer of blood glucose monitoring systems. In third place was the $1.9 billion acquisition of Alphabet-backed Flatiron Health, an electronic health record software specialist with a focus on oncology, by Swiss drugmaker Roche Holding, adding to its existing stake, for a total value of $2.1 billion.

The two other private equity deals that made it into the top ten biggest transactions were the $1.05 billion cash acquisition of General Electric’s health-care technology unit by Veritas Capital and Vista Equity Partners’ investment in software company Allocate.

The future of healthtech M&A

Jonathan Simnett, continued:

“Ageing populations, increasing patient demands and the rise of lifestyle diseases, coupled with pressure on service delivery budgets are forcing public and private healthcare providers faced with unsustainable care models to innovate to improve the quality of delivery and lower costs.

“This is prompting tech giants, including Amazon, Apple, Google and IBM to target the healthcare sector in competition with private equity, but they’ll all face strong competition for deals from incumbent healthtech providers, many of whom are under growing pressure to maintain their top-line organic growth and sharpen their market focus. This is all good news for healthtech companies considering an exit in coming months.”